Lennox Gastaut Syndrome - Pipeline Insight, 2024

This “Lennox-Gastaut Syndrome (LGS) - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Lennox-Gastaut Syndrome (LGS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Lennox-Gastaut Syndrome (LGS) Understanding

Lennox-Gastaut Syndrome (LGS): Overview

Lennox-Gastaut syndrome (LGS) is a severe form of epilepsy that typically becomes apparent during infancy or early childhood. Children with Lennox-Gastaut syndrome may also develop cognitive dysfunction, delays in reaching developmental milestones and behavioral problems. The symptoms of Lennox-Gastaut syndrome usually begin during infancy or childhood, most often between 3 to 5 years of age. Most affected individuals experience multiple types of seizures, multiple times throughout the day. A diagnosis of Lennox-Gastaut syndrome is usually made based upon a thorough clinical evaluation, a detailed patient history and a complete physical and neurological evaluation including advanced imaging techniques, such as electroencephalography (EEG) and magnetic resonance imaging (MRI). The three main forms of treatment of Lennox-Gastaut syndrome are anti-epileptic drugs (AEDs), dietary therapy (typically the ketogenic diet) or device/surgery (VNS therapy or corpus callosotomy). Rarely, resective surgery is an option.

Lennox-Gastaut Syndrome (LGS) - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lennox-Gastaut Syndrome (LGS) pipeline landscape is provided which includes the disease overview and Lennox-Gastaut Syndrome (LGS) treatment guidelines. The assessment part of the report embraces, in depth Lennox-Gastaut Syndrome (LGS) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lennox-Gastaut Syndrome (LGS) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Lennox-Gastaut Syndrome (LGS) R&D. The therapies under development are focused on novel approaches to treat/improve Lennox-Gastaut Syndrome (LGS).

Lennox-Gastaut Syndrome (LGS) Emerging Drugs Chapters

This segment of the Lennox-Gastaut Syndrome (LGS) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Lennox-Gastaut Syndrome (LGS) Emerging Drugs

Soticlestat: Takeda Soticlestat is a potent, highly selective, oral, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H). In March 2021, Takeda Pharmaceutical Company and Ovid Therapeutics announced that Takeda has entered into an exclusive agreement under which Takeda secured global rights at closing from Ovid to develop and commercialize the investigational medicine soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic encephalopathies, including Dravet Syndrome and Lennox-Gastaut syndrome (LGS). The drug is in Phase III clinical studies for the treatment of Lennox-Gastaut Syndrome(LGS).

Lennox-Gastaut Syndrome (LGS): Therapeutic Assessment

This segment of the report provides insights about the different Lennox-Gastaut Syndrome (LGS) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Lennox-Gastaut Syndrome (LGS)

There are approx. 10+ key companies which are developing the therapies for Lennox-Gastaut Syndrome (LGS). The companies which have their Lennox-Gastaut Syndrome (LGS) drug candidates in the most advanced stage, i.e. Phase III include, Takeda.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Lennox-Gastaut Syndrome (LGS) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lennox-Gastaut Syndrome (LGS): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Lennox-Gastaut Syndrome (LGS) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lennox-Gastaut Syndrome (LGS) drugs.

Lennox-Gastaut Syndrome (LGS) Report Insights

• Lennox-Gastaut Syndrome (LGS) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Lennox-Gastaut Syndrome (LGS) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Lennox-Gastaut Syndrome (LGS) drugs?
• How many Lennox-Gastaut Syndrome (LGS) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lennox-Gastaut Syndrome (LGS)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Lennox-Gastaut Syndrome (LGS) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Lennox-Gastaut Syndrome (LGS) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Takeda
• Marinus Pharmaceuticals
• SK biopharmaceuticals
• CuroNZ
• TAHO Pharmaceuticals
• Axium Pharmaceuticals

Key Products

• Soticlestat
• Ganaxolone
• Carisbamate
• NRP 2945
• TAH-6601

This product will be delivered within 1-3 business days.